Published in Pharma Law Weekly, May 24th, 2005
More specifically, CepTor has filed to receive an additional 20 years of compound protection for oral delivery of Myodur with accompanied use protection in Duchenne muscular dystrophy (DMD) and other neuromuscular diseases.
William Pursley, CepTor's chairman and CEO stated, "Protecting our property remains a never-ending priority. We are unaware of any other specific muscle cell targeted, protease inhibiting compounds being used or developed to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.